The Cure Parkinson’s Trust (CPT) funds work to slow, stop or even reverse Parkinson’s (PD). We fund both clinical trials and preclinical work which seeks to open up new avenues in the search for a cure - all of which have the potential to make a real difference to the lives of people living with Parkinson's. CPT was founded and is led by people with Parkinson’s which means that patient experience informs all our work. 

Liraglutide, Lixisenatide, Exenatide and Bydureon belong to a group of safe and well-tolerated drugs called GLP-1 agonists. They are used to treat type 2 diabetes and in recent years there has been research based evidence to suggest that they show great promise as potential new treatments for Parkinson's.

Exenatide is a type 2 diabetes drug that has shown great promise as a neuroprotective agent in laboratory experiments (*1). Parkinson’s patients given Exenatide for one year continued to show a level of improvement compared to the control group a year after discontinuing treatment. On the strength of these results, a follow-on trial was designed and funded by The Michael J. Fox Foundation for Parkinson’s Research using a similar but weekly dosed drug Bydureon (AstraZeneca) led by Prof. Tom Foltynie at University College London (UCLH).

This trial has now finished, but further analysis of results needs to be undertaken, collaborative partnerships are to be progressed and funding is urgently required to do this.

Lixisenatide and Liraglutide are two injectable diabetes treatments which have been moved into Parkinson’s clinical trials. CPT and the Van Andel Research Institute are collaborating with the lead investigators in France and the U.S. as well as the pharmaceutical companies who own the drugs, Sanofi and NovoNordisk. Two distinct trials have been designed with targeted populations of people with Parkinson’s to investigate this potentially important new approach to treating Parkinson's.

Please help us drive forward our research in this pioneering GLP-1 drug re-purposing initiative by donating today - thank you.

Publications for further information:

*1. Aviles-Olmos I, Dickson J, Kefalopoulou Z, Djamshidian A, Kahan J, Ell P, Whitton P, Wyse R, Isaacs T, Lees A, Limousin P, Foltynie T. 2014. Motor and cognitive advantages persist 12 months after exendatide exposure in Parkinson’s disease. J Parkinson’s Dis 4(3):337–344